AtriCure to Participate at the Oppenheimer 31st Annual Healthcare Conference

Rhea-AI Summary

AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), announced its participation in the Oppenheimer 31st Annual Healthcare Conference. The presentation is scheduled for March 16, 2021, at 1:10 p.m. Eastern Time. AtriCure offers innovative solutions, including the Isolator® Synergy™ Ablation System, the first FDA-approved device for treating persistent Afib, and the AtriClip® Left Atrial Appendage Exclusion System, the most widely sold LAA management device globally. For more details, visit AtriCure's investor page.

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Oppenheimer 31^st Annual Healthcare Conference.

AtriCure’s management is scheduled to present on Tuesday, March 16, 2021, at 1:10 p.m. Eastern Time. Interested parties may access a live and archived audio webcast of the presentation by visiting the “Investors” section of the company’s website at https://ir.atricure.com.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator^® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip^® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210302006057/en/

FAQ

When is AtriCure's presentation at the Oppenheimer Healthcare Conference?

AtriCure's presentation is scheduled for March 16, 2021, at 1:10 p.m. Eastern Time.

What is AtriCure known for?

AtriCure is known for its innovative technologies for the treatment of atrial fibrillation (Afib) and left atrial appendage (LAA) management.

What products does AtriCure offer for Afib treatment?

AtriCure offers the Isolator® Synergy™ Ablation System, FDA-approved for persistent Afib, and the AtriClip® LAA Exclusion System, widely sold for LAA management.

How can I access AtriCure's conference presentation?

You can access AtriCure's presentation live and archived via their investor section at https://ir.atricure.com.

What does Afib affect globally?

Atrial fibrillation (Afib) affects more than 33 million people worldwide.